LIFECORE BIOMEDICAL, INC. quarterly report, Q3 FY2009

Business Context and Reporting Period

Company: Landec Corporation (Note: Input metadata referenced "LIFECORE BIOMEDICAL, INC.", but the filing text is for Landec Corporation).

Filing Type: Form 10-Q (Quarterly Report).

Period: Fiscal quarter ended August 30, 2009.

Business Overview: Landec designs, develops, and sells temperature-activated polymer products. Operations are divided into three segments: Food Products Technology (Apio, Inc., selling fresh-cut produce and packaging), Commodity Trading (buy/sell of whole produce), and Technology Licensing (Intellicoat seed coatings and Intelimer polymers).

Key Financial Metrics

Metric Q1 2010 (Ended Aug 30, 2009) Q1 2009 (Ended Aug 31, 2008)
Total Revenues $60.9 million $71.8 million
Gross Profit $8.9 million $10.1 million
Gross Margin 14.6% 14.1%
Operating Income $3.4 million $4.6 million
Net Income (Common Stockholders) $2.2 million $2.8 million
Diluted EPS $0.08 $0.11
Cash & Equivalents (End of Period) $4.0 million $45.7 million
Marketable Securities $65.5 million $22.5 million
Total Assets $163.7 million $153.5 million
Total Liabilities $33.6 million $26.3 million
Operating Cash Flow $4.3 million $2.2 million

Material Changes vs. Prior Period

  • Revenue Decline: Total revenues decreased 15% to $60.9 million. This was driven by a 33% drop in Commodity Trading revenues (due to reduced export volumes and exiting domestic Wal-Mart business) and a 4% decline in Apio Value-Added revenues (partially due to a 13-week vs. 14-week period comparison).
  • Liquidity Shift: Cash and cash equivalents dropped significantly from $43.5 million to $4.0 million. This decrease was primarily due to a net purchase of $43.0 million in marketable securities and $1.3 million in capital expenditures for facility expansion.
  • Working Capital: Accounts receivable increased by $4.0 million, and inventories increased by $2.6 million due to seasonal buildup. Accounts payable increased by $7.2 million due to timing of payments.
  • Profitability: Net income applicable to common stockholders decreased 23% to $2.2 million, reflecting lower revenues and a slight decrease in the effective tax rate (37% vs 40% prior year).

Guidance, Outlook, and Risks

  • Outlook: Management believes existing cash, cash equivalents, and marketable securities are sufficient to finance operations for at least the next twelve months. No specific numerical guidance was provided in this filing.
  • Strategic Focus: Continued expansion of Apio's value-added processing facility and automation. Focus on commercializing Intellicoat seed coatings with Monsanto and Intelimer polymers for industrial and medical applications.
  • Risks:
    • Economic Conditions: Global economic slowdown and volatility may reduce demand and impact customer creditworthiness.
    • Customer Concentration: Top five customers accounted for 50% of revenues; Costco Wholesale Corp. alone accounted for 19%.
    • Seasonality & Weather: Operations are subject to weather conditions affecting crop yields and commodity prices.
    • Regulatory: Subject to FDA, USDA, and environmental regulations; potential for product liability claims.
  • Unusual Items: The filing notes a significant shift in investment strategy, moving cash into marketable securities (municipal bonds and CDs) totaling $65.5 million.

Investor Verification Checklist

  • Cash Deployment: Verify the rationale and expected yield for the $43 million net purchase of marketable securities given the drop in liquid cash.
  • Customer Concentration: Assess the risk exposure related to Costco (19% of revenue) and the top five customers (50% of revenue).
  • Commodity Trading Exit: Confirm the status of the planned exit from the domestic buy/sell business with Wal-Mart and its long-term impact on revenue stability.
  • Inventory Levels: Review the $2.6 million increase in inventory to ensure it aligns with seasonal demand and does not indicate obsolescence risks.
  • Goodwill Valuation: Monitor the $27.4 million goodwill balance for potential impairment triggers given the economic volatility and revenue declines.